We are live on ! Find out more
AKCA

Akcea Therapeutics Inc
AKCA

Delisted

AKCA was delisted on the 9th of October, 2020.

Back to rankings

57 hedge funds and large institutions have $526M invested in Akcea Therapeutics Inc in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $337M → $526M (+$189M)

19% more call options, than puts

Call options by funds: $1.52M | Put options by funds: $1.28M

0% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 10

10% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 21

2% less funds holding

Funds holding: 58 → 57 (-1)

Holders
57
Holders Change
-1
Holders Change %
-1.72%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
19
Reduced
21
Closed
10
Calls
$1.52M
Puts
$1.28M
Net Calls
+$237K
Net Calls Change
+$237K

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$24.6M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.7M
3
PA
Perceptive Advisors
New York
+$2.09M
4
BG
Bellevue Group
Switzerland
+$1.05M
5
AGA
Altrinsic Global Advisors
Connecticut
+$814K

Top Sellers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
-$5.27M
2
GIM
Granahan Investment Management
Massachusetts
-$3.37M
3
CS
Candriam SCA
Luxembourg
-$1.99M
4
IHM
Iguana Healthcare Management
New York
-$1.74M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Acadian Asset Management
51
Acadian Asset Management
Massachusetts
$4K +$3.21K +149 New
Citigroup
52
Citigroup
New York
$3K -$86 -4 -3%
CG
53
Cutler Group
California
$3K +$2.73K +127 New
SIM
54
Sonora Investment Management
Arizona
$1.28K – – –
QI
55
QS Investors
New York
$1K – – –
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$1K +$1.23K +57 +2,850%
GIM
57
Granahan Investment Management
Massachusetts
– -$3.37M -194,376 Closed
CS
58
Candriam SCA
Luxembourg
– -$1.99M -114,571 Closed
IHM
59
Iguana Healthcare Management
New York
– -$1.74M -100,000 Closed
USAA
60
United Services Automobile Association
Texas
– -$1.16M -66,680 Closed
OAM
61
Oxford Asset Management
United Kingdom
– -$496K -27,566 Closed
AAP
62
Ardsley Advisory Partners
Connecticut
– -$260K -15,000 Closed
ARTA
63
A.R.T. Advisors
New York
– -$239K -13,800 Closed
SG Americas Securities
64
SG Americas Securities
New York
– -$121K -6,951 Closed
Macquarie Group
65
Macquarie Group
Australia
– -$31K -1,800 Closed
DCM
66
Delpha Capital Management
New York
– -$26K -1,521 Closed
1 2
3

AKCA Hedge Fund Activity: Q1 2018 in Review

57 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q1 2018, worth a combined $526M — up 56% from $337M a quarter earlier.

Fund positioning in AKCA was balanced in Q1 2018: 10 funds opened new positions, 10 closed out, 19 added to existing stakes and 21 trimmed.

The largest buyer was BB Biotech, adding an estimated $24.6M. The largest seller was Eventide Asset Management, cutting an estimated $5.27M.

  • 57 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q1 2018, down from 58 in Q4 2017.
  • Funds reported $526M of Akcea Therapeutics Inc stock for Q1 2018, up 56% quarter-over-quarter.
  • 10 funds opened new Akcea Therapeutics Inc positions in Q1 2018 and 10 closed out, a net change of 0 holders.
  • The largest Akcea Therapeutics Inc buyer in Q1 2018 was BB Biotech, an estimated $24.6M added.
  • The largest Akcea Therapeutics Inc seller in Q1 2018 was Eventide Asset Management, an estimated $5.27M sold.

Based on aggregated 13F filings for Q1 2018.